| scholarly article | Q13442814 |
| P50 | author | José Manuel Lopes | Q42913152 |
| Helena Pópulo | Q47823801 | ||
| Sandra Tavares | Q59121335 | ||
| Alexandra Faustino | Q59312717 | ||
| Paula Soares | Q37840702 | ||
| P2093 | author name string | Joana B Nunes | |
| P2860 | cites work | Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease | Q42815596 |
| Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma | Q43154862 | ||
| Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas | Q44763084 | ||
| mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. | Q54637612 | ||
| Melanoma | Q56428909 | ||
| Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas | Q60527002 | ||
| Biologic behavior of ocular malignant melanoma and comparison with melanoma of the head and neck | Q71348510 | ||
| Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi | Q24646052 | ||
| Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin | Q24811525 | ||
| Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype | Q27334924 | ||
| Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma | Q28472048 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| New colorimetric cytotoxicity assay for anticancer-drug screening | Q29615418 | ||
| BRAFE600-associated senescence-like cell cycle arrest of human naevi | Q29619550 | ||
| The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society | Q31995716 | ||
| Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals | Q33760578 | ||
| Loitering with intent: new evidence for the role of BRAF mutations in the proliferation of melanocytic lesions | Q35890420 | ||
| Developments in the management of uveal melanoma | Q35970013 | ||
| Human melanocyte biology, toxicology, and pathology | Q36314397 | ||
| Cutaneous melanoma: available therapy for metastatic disease | Q36365463 | ||
| Predicted mechanisms of resistance to mTOR inhibitors | Q36585744 | ||
| Current topics in melanoma | Q36726152 | ||
| Melanoma biology and new targeted therapy | Q36742015 | ||
| The genome and epigenome of malignant melanoma | Q37016230 | ||
| Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner | Q39325158 | ||
| mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. | Q39355399 | ||
| Molecular basis of a novel oncogenic mutation in GNAO1 | Q39593006 | ||
| Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. | Q40005196 | ||
| Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells | Q40005203 | ||
| Establishment and characterization of an uveal-melanoma cell line. | Q40978454 | ||
| Establishment and characterization of primary and metastatic uveal melanoma cell lines | Q41199649 | ||
| Biological assays for Ras transformation | Q41388691 | ||
| Cellular senescence in naevi and immortalisation in melanoma: a role for p16? | Q42016240 | ||
| Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 | ||
| Studies of tumor-infiltrating lymphocytes from a human choroidal melanoma | Q42808147 | ||
| P304 | page(s) | e104 | |
| P577 | publication date | 2013-07-23 | |
| P1433 | published in | PeerJ | Q2000010 |
| P1476 | title | GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells | |
| P478 | volume | 1 |
| Q55217220 | Melanoma treatment in review. |
| Q37588399 | Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior |
| Q38874710 | Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy. |
| Q89511646 | The Role of Immune Checkpoint Blockade in Uveal Melanoma |
Search more.